Population based prenatal screening for the fragile X syndrome.
Palomaki
G E
GE
Foundation for Blood Research, Scarborough, Maine 04070-0190, USA.
D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1; D005600:Fragile X Syndrome / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D006580:Genetic Carrier Screening; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008607:Intellectual Disability / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D008297:Male; D009419:Nerve Tissue Proteins / Q000235:genetics*; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods; D011247:Pregnancy; D011296:Prenatal Diagnosis; D015995:Prevalence; D011336:Probability; D016601:RNA-Binding Proteins; D012727:Sex Characteristics; D018911:Trinucleotide Repeats; D006113:United Kingdom / Q000453:epidemiology; D014960:X Chromosome
D051860:Fragile X Messenger Ribonucleoprotein 1; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; C497683:FMR1 protein, human